Abstract
Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR ) subtypes as master regulators of lipid, lipoprotein, and glucose homeostasis, and the rapid development of parallel screening assay methods to evaluate transactivation and/or binding activity toward individual PPAR subtypes, have provided an opportunity to develop novel PPAR agonists with characteristic subtype selectivity. Such agonists are candidates for the treatment of metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, and hypertension. This review focuses on the recent literature dealing with medicinal-chemical strategies to identify PPARδ- selective agonists and PPARδ/α dual agonists. Recent progress of studies on selective modulators of PPARγM (SPPARγM) is also briefly reviewed.
Keywords: Peroxisome proliferator-activated receptor, PPAR, PPARδ agonist, PPARδ/α dual agonist, SPPARγM
Current Bioactive Compounds
Title: Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Volume: 2 Issue: 2
Author(s): Hiroyuki Miyachi
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, PPAR, PPARδ agonist, PPARδ/α dual agonist, SPPARγM
Abstract: Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR ) subtypes as master regulators of lipid, lipoprotein, and glucose homeostasis, and the rapid development of parallel screening assay methods to evaluate transactivation and/or binding activity toward individual PPAR subtypes, have provided an opportunity to develop novel PPAR agonists with characteristic subtype selectivity. Such agonists are candidates for the treatment of metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, and hypertension. This review focuses on the recent literature dealing with medicinal-chemical strategies to identify PPARδ- selective agonists and PPARδ/α dual agonists. Recent progress of studies on selective modulators of PPARγM (SPPARγM) is also briefly reviewed.
Export Options
About this article
Cite this article as:
Miyachi Hiroyuki, Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome, Current Bioactive Compounds 2006; 2 (2) . https://dx.doi.org/10.2174/157340706777435176
DOI https://dx.doi.org/10.2174/157340706777435176 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Current Protein & Peptide Science Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Synthesis and Binding Properties of New Endothelin Receptor Ligands
Letters in Drug Design & Discovery Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Calcific Aortic Valve Disease and Hypertension
Current Hypertension Reviews Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis
Current Pharmaceutical Design Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Oral Fast-Release Solid Dispersion-Paradigm Shift to Nanoparticles
Recent Patents on Drug Delivery & Formulation Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Editorial (Hot Topic: Autosomal Dominant Polycystic Kidney Disease: Cardiovascular Complications)
Current Hypertension Reviews Smoking, Estradiol Metabolism and Hormone Replacement Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design A Randomized, Placebo-controlled, Triple-blind Study to Determine the Effect of Farlong Ginseng Plus® NotoGinseng Extract on Cholesterol and Blood Pressure
Current Nutraceuticals Screening and Preponderance of Peptic Ulcer and its Contributing Risk Factors Among Basrah City Residents in Iraq
Current Drug Safety